Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

Core Insights - Alvotech has appointed Linda Jónsdóttir as the new Chief Financial Officer (CFO), bringing extensive international experience in finance and corporate leadership [1][2][3] - Joel Morales, the previous CFO since 2020, will step down to focus on family but will remain in an advisory role to ensure a smooth transition [1][4] Company Overview - Alvotech is a global biotech company focused on developing and manufacturing biosimilar medicines, aiming to be a leader in the biosimilar market [5] - The company has two approved biosimilars, Humira® (adalimumab) and Stelara® (ustekinumab), and a pipeline of nine disclosed biosimilar candidates targeting various diseases [5] - Alvotech has established strategic commercial partnerships across multiple regions, including the United States, Europe, Japan, and parts of Asia and South America [5] Leadership Transition - Linda Jónsdóttir has a strong background, having held senior roles at Marel, including CFO and COO, and has experience on various boards [2][3] - Robert Wessman, CEO of Alvotech, expressed confidence in Linda's ability to support the company's growth and evolution [3] - Joel Morales acknowledged the transformation of Alvotech during his tenure, highlighting the company's transition to a public and profitable entity [4]